COVID-19: Medication therapy: Difference between revisions
| Line 4: | Line 4: | ||
*[[Antivirals]] | *[[Antivirals]] | ||
**[[Lopinavir]]/[[Ritonavir]] - Known in the U.S as Kaletra, this HIV medication has been widely used in China to treat COVID patients.<ref>https://www.reuters.com/article/us-health-coronavirus-china-wuhan-hospit/key-china-coronavirus-hospital-says-hiv-drug-beneficial-to-patients-idUSKCN21R1LX</ref>. An RCT with 199 confirmed COVID-19 positive patients concluded that there was no benefit to treating hospitalized patients with [[Lopinavir]]/[[Ritonavir]] versus supportive care.<ref>Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., ... & Li, X. (2020). A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine.</ref> | **[[Lopinavir]]/[[Ritonavir]] - Known in the U.S as Kaletra, this HIV medication has been widely used in China to treat COVID patients.<ref>https://www.reuters.com/article/us-health-coronavirus-china-wuhan-hospit/key-china-coronavirus-hospital-says-hiv-drug-beneficial-to-patients-idUSKCN21R1LX</ref>. An RCT with 199 confirmed COVID-19 positive patients concluded that there was no benefit to treating hospitalized patients with [[Lopinavir]]/[[Ritonavir]] versus supportive care.<ref>Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., ... & Li, X. (2020). A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine.</ref> | ||
**[[Remdesivir]] | **[[Remdesivir]] - Previously used to treat Ebola<ref>Auwaerter. Johns Hopkins Antibiotic guide. Coronavirus COVID-19. April 8 2020</ref> this medication inhibits viral RNA polymerase and has shown some promisinng invitro activity against [[SARS-CoV-2]]. A recent small study among 53 patients with severe symptoms from COVID-19 were given [[Remdesivir]] for compassionate use. 68% percent of patients showed some clinical improvement.<ref>Grein, J., Ohmagari, N.,...Oda, R (2020). Compassionate Use of Remdesivir for Patients with Severe COVID-19. New England Journal of Medicine.</ref> | ||
*[[Chloroquine]] | *[[Chloroquine]] | ||
*[[Immunomodulators]] | *[[Immunomodulators]] | ||
Revision as of 23:58, 10 April 2020
Outpatient Treatment
Treatment for those infected with SARS-CoV-2 focuses on supportive care which includes symptomatic management, hand hygiene and social distancing. While many treatments are under investigation there is no proven efficacy of any drug for human as of April 8th 2020.[1]
- Symptomatic management
- Antivirals
- Lopinavir/Ritonavir - Known in the U.S as Kaletra, this HIV medication has been widely used in China to treat COVID patients.[2]. An RCT with 199 confirmed COVID-19 positive patients concluded that there was no benefit to treating hospitalized patients with Lopinavir/Ritonavir versus supportive care.[3]
- Remdesivir - Previously used to treat Ebola[4] this medication inhibits viral RNA polymerase and has shown some promisinng invitro activity against SARS-CoV-2. A recent small study among 53 patients with severe symptoms from COVID-19 were given Remdesivir for compassionate use. 68% percent of patients showed some clinical improvement.[5]
- Chloroquine
- Immunomodulators
- Vaccine
Inpatient Treatment
See Also
COVID-19 Pages
- COVID-19 (main)
References
- ↑ Auwaerter. Johns Hopkins Antibiotic guide. Coronavirus COVID-19. April 8 2020
- ↑ https://www.reuters.com/article/us-health-coronavirus-china-wuhan-hospit/key-china-coronavirus-hospital-says-hiv-drug-beneficial-to-patients-idUSKCN21R1LX
- ↑ Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., ... & Li, X. (2020). A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine.
- ↑ Auwaerter. Johns Hopkins Antibiotic guide. Coronavirus COVID-19. April 8 2020
- ↑ Grein, J., Ohmagari, N.,...Oda, R (2020). Compassionate Use of Remdesivir for Patients with Severe COVID-19. New England Journal of Medicine.